工程化CRISPR-Cas系统用于转录调控与精准分子诊断:进展、挑战及微流控整合新趋势
本综述阐述工程化CRISPR-Cas系统如何从基因组编辑工具发展为转录调控、表观遗传工程、分子成像和超灵敏核酸检测的多功能平台。文章重点介绍dCas9和dCas12等催化失活Cas蛋白通过CRISPRi/CRISPRa实现可逆基因调控,以及Cas12和Cas13的旁切活性衍生的SHERLOCK、DETECTR和FELUDA诊断平台在SARS-CoV-2、寨卡病毒和结核分枝杆菌检测中的应用。综述还讨论CRISPR与微流控、生物传感器等集成的趋势,并指出脱靶效应、递送效率、诊断标准化、规模化生产和临床转化等现存挑战。
要点
- dCas9和dCas12保留靶序列结合能力但不切割DNA,可通过CRISPRi/CRISPRa可逆调控基因表达。
- Cas12和Cas13的旁切活性催生SHERLOCK、DETECTR和FELUDA等高灵敏、高特异性核酸检测平台。
- CRISPR诊断平台已用于SARS-CoV-2、寨卡病毒和结核分枝杆菌检测,在资源有限场景的即时检测中具重要价值。
核心结论
- 工程化CRISPR-Cas系统已从基因组编辑工具拓展为涵盖转录调控、表观遗传工程、诊断、成像及微流控整合的多功能平台。
研究设计与样本
- 本文为综述,围绕工程化CRISPR-Cas系统在转录调控与精准分子诊断中的进展、挑战及微流控整合趋势进行论述。
主要发现
- 催化失活的dCas9和dCas12保留DNA序列特异性结合能力但不切割DNA,可通过CRISPRi或CRISPRa进行可逆基因表达调控。
- Cas12和Cas13的旁切活性被用于构建SHERLOCK、DETECTR和FELUDA等CRISPR诊断平台,可高灵敏、高特异检测目标DNA/RNA序列。
- 上述平台已在SARS-CoV-2、寨卡病毒和结核分枝杆菌等病原体检测中展示应用价值,适用于资源有限条件下的即时检测。
- CRISPR系统正日益与表观遗传调控因子、荧光显微镜方法、生物传感器及集成微流控的芯片实验室平台结合,以改进分子分析和自动化诊断。
临床怎么用
- 在资源有限场景下,可考虑将基于Cas12/Cas13旁切活性的CRISPR诊断平台用于病原体核酸的即时检测。
- dCas9/dCas12介导的CRISPRi/CRISPRa可用于功能基因组研究和合成生物学应用中的可逆基因表达调控。
- CRISPR诊断技术与微流控、生物传感器整合有望提升分子分析的自动化程度和诊断效率。
局限性
- 当前CRISPR技术仍面临脱靶效应、递送效率、诊断标准化、规模化生产及临床转化等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CRISPR-Cas technology has evolved rapidly from a bacterial adaptive immune system to transformative use in molecular diagnostic and genomic engineering. Beyond traditional genome-editing capabilities, newly engineered versions of CRISPR/Cas can be used for programmable transcriptional regulation, epigenetic modification, molecular imaging, and ultrasensitive nucleic acid detection. Specifically, catalytic-inactive Cas proteins like dCas9 and dCas12 retain their ability to bind specific sequences on DNA but do not cleave it. Therefore, these proteins can be reversibly regulated by either CRISPRi or CRISPRa to alter gene expression. Thus, they represent powerful tools for both functional genomic studies and synthetic biological applications. Advances in CRISPR engineering have recently greatly increased the diagnostic potential of Cas12 and Cas13 enzymes. For example, collateral cleavage activity allowed the creation of CRISPR-based diagnostic platforms (SHERLOCK, DETECTR and FELUDA), which can detect target DNA/RNA sequences at high sensitivity and specificity. Moreover, they were demonstrated to work in detecting several infectious pathogens (SARS-CoV-2, Zika virus, and M. tuberculosis) and thus have significant value in point-of-care testing, especially when there is limited availability of resources. CRISPR systems are also being combined with increasing frequency with epigenetic regulators, fluorescence microscopy methods, biosensors, and lab-on-a-chip platforms that incorporate microfluidics to provide improved molecular analysis and automated diagnosis. The purpose of this review is to describe how engineered CRISPR-Cas systems have been developed from primarily genome editing tools into multi-functional platforms for transcriptional regulation, epigenetic engineering, diagnostics, imaging, and emerging microfluidic integrations. Additionally, this review will address some of the current challenges that exist with using CRISPR-based technologies, including off-target effects, delivery efficiency, diagnostic standardization, scaling up production, and translating these technologies clinically.
引用
- Rambabu I, Baskar G, Suliman M, et al. Engineered CRISPR-Cas systems for transcriptional regulation and precision molecular diagnostics: advances, challenges, and emerging microfluidic integration. Clin Chim Acta. 2026. PMID: 42263803. doi:10.1016/j.cca.2026.121145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。